Valuation: AstraZeneca PLC

Market Cap 257B 226B 213B 194B 363B 24,626B 366B 2,555B 987B 12,566B 963B 942B 40,380B P/E 2026 *
21.2x
P/E 2027 * 18.5x
Enterprise Value 276B 243B 230B 208B 391B 26,516B 394B 2,751B 1,062B 13,531B 1,037B 1,015B 43,480B EV / Sales 2026 *
4.37x
EV / Sales 2027 * 4.01x
Free-Float
96.62%
Yield 2026 *
2.01%
Yield 2027 * 2.13%
1 day+0.75%
1 week+0.73%
Current month+5.56%
1 month+5.03%
3 months-9.76%
6 months-8.20%
Current year-3.11%
1 week 1,614
Extreme 1614
1,668.5
1 month 1,507
Extreme 1507
1,668.5
Current year 1,467
Extreme 1467
1,925.5
1 year 1,385
Extreme 1385
1,925.5
3 years 1,226
Extreme 1226
1,925.5
5 years 978.1
Extreme 978.1
1,925.5
10 years 461.3
Extreme 461.3
1,925.5
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Compliance Officer - 01/01/2023
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
+0.61%+0.73% - - 258B
+0.11%+1.71%+63.08%+117.61% 1,055B
+0.27%+0.92%+49.74%+73.35% 654B
+0.73%+0.68%+19.32%+74.90% 467B
-1.36%-0.39%+40.20%+41.03% 348B
+1.34%+5.47%+23.37%+31.30% 275B
-0.48%-0.06%+13.56%+12.36% 258B
+0.85%+6.35%+52.62%+54.39% 224B
+0.85%+1.10%+35.15%+101.82% 187B
-0.30%-10.41%-27.62%-61.04% 171B
Average +0.40%+0.74%+29.94%+49.52% 404.26B
Weighted average by Cap. +0.37%+1.32%+40.03%+69.79%

Financials

2026 *2027 *
Net sales 63.17B 55.55B 52.53B 47.65B 89.49B 6,063B 90B 629B 243B 3,094B 237B 232B 9,942B 67.01B 58.94B 55.73B 50.55B 94.93B 6,433B 95.48B 667B 258B 3,282B 252B 246B 10,548B
Net income 12.04B 10.59B 10.02B 9.08B 17.06B 1,156B 17.16B 120B 46.32B 590B 45.22B 44.24B 1,896B 13.77B 12.11B 11.45B 10.39B 19.51B 1,322B 19.63B 137B 52.97B 675B 51.71B 50.59B 2,168B
Net Debt 19.69B 17.32B 16.38B 14.86B 27.9B 1,890B 28.06B 196B 75.74B 965B 73.94B 72.34B 3,100B 11.93B 10.49B 9.92B 9B 16.9B 1,145B 17B 119B 45.88B 584B 44.79B 43.82B 1,878B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
29/09/26 SEK 1,650.50 +0.61% 536,388
25/09/26 SEK 1,640.50 +0.64% 392,299
24/09/26 SEK 1,630.00 -0.58% 353,792
23/09/26 SEK 1,639.50 -1.65% 368,047
22/09/26 SEK 1,667.00 +1.31% 414,094
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
166.19USD
Average target price
211.41USD
Spread / Average Target
+27.21%

Quarterly revenue - Rate of surprise